Compare SHIM & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | ALDX |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.2M | 124.9M |
| IPO Year | 2023 | 2014 |
| Metric | SHIM | ALDX |
|---|---|---|
| Price | $3.70 | $1.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 133.6K | ★ 2.1M |
| Earning Date | 05-14-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | 40.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $492,844,000.00 | N/A |
| Revenue This Year | $13.99 | N/A |
| Revenue Next Year | $6.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.63 | N/A |
| 52 Week Low | $1.58 | $1.07 |
| 52 Week High | $6.76 | $6.18 |
| Indicator | SHIM | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 38.70 |
| Support Level | $3.43 | $1.49 |
| Resistance Level | $4.10 | $1.91 |
| Average True Range (ATR) | 0.34 | 0.19 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 17.20 | 6.45 |
Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.